News Coverage 10.28.20 Share on Twitter Share on Facebook Share on LinkedIn Blood Test Could Predict the Best Type of Treatment for Metastatic Melanoma A new study finds that people with lower levels of tumor DNA in their blood stream may be better candidates for immune checkpoint inhibitors as a first treatment. Determining Treatment for Metastatic Melanoma A blood test or “liquid biopsy” can pick up bits of tumor DNA in your bloodstream. Lower levels of circulating tumor DNA could mean you’ll have a better response to immune checkpoint inhibitors for metastatic melanoma. Use of liquid biopsy is increasing across all phases of cancer screening, diagnosis and treatment. Related Announcement PICI 2024: Collaborative Breakthroughs in Cancer Immunotherapy Announcement, Press Release Parker Institute Awards $525,000 to Advance Diverse Talent in Cancer Research Announcement PICI Network Investigators Propel Immunotherapy Progress at SITC 2024
Announcement, Press Release Parker Institute Awards $525,000 to Advance Diverse Talent in Cancer Research